These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

612 related articles for article (PubMed ID: 9611063)

  • 21. Epithelial ovarian tumors of borderline malignancy.
    Chao TM; Yen MS; Chao KC; Ng HT
    Zhonghua Yi Xue Za Zhi (Taipei); 1996 Aug; 58(2):97-102. PubMed ID: 8915111
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Factors associated with misdiagnosis of frozen section of mucinous borderline ovarian tumor.
    Zhang W; Jia S; Xiang Y; Yang J; Jia C; Leng J
    J Int Med Res; 2019 Jan; 47(1):96-104. PubMed ID: 30198356
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serum CA 125, carcinoembryonic antigen, and CA 19-9 as tumor markers in borderline ovarian tumors.
    Engelen MJ; de Bruijn HW; Hollema H; ten Hoor KA; Willemse PH; Aalders JG; van der Zee AG
    Gynecol Oncol; 2000 Jul; 78(1):16-20. PubMed ID: 10873403
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mucinous tumors of the ovary: a clinicopathologic study of 196 borderline tumors (of intestinal type) and carcinomas, including an evaluation of 11 cases with 'pseudomyxoma peritonei'.
    Lee KR; Scully RE
    Am J Surg Pathol; 2000 Nov; 24(11):1447-64. PubMed ID: 11075847
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Staging with Unilateral Salpingo-Oophorectomy and Expert Pathological Review Result in No Recurrences in a Series of 81 Intestinal-Type Mucinous Borderline Ovarian Tumors.
    Dewilde K; Moerman P; Leunen K; Amant F; Neven P; Vergote I
    Gynecol Obstet Invest; 2018; 83(1):65-69. PubMed ID: 28689208
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Value of Serum CA125 in the Diagnosis of Borderline Tumors of the Ovary: A Subanalysis of the Prospective Multicenter ROBOT Study.
    Fotopoulou C; Sehouli J; Ewald-Riegler N; de Gregorio N; Reuss A; Richter R; Mahner S; Kommoss F; Schmalfeldt B; Fehm T; Hanker L; Wimberger P; Canzler U; Pfisterer J; Kommoss S; Hauptmann S; du Bois A;
    Int J Gynecol Cancer; 2015 Sep; 25(7):1248-52. PubMed ID: 25978292
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High levels of pretreatment CA125 are associated to improved survival in high grade serous ovarian carcinoma.
    Morales-Vásquez F; Pedernera E; Reynaga-Obregón J; López-Basave HN; Gómora MJ; Carlón E; Cárdenas S; Silva-Ayala R; Almaraz M; Méndez C
    J Ovarian Res; 2016 Jul; 9(1):41. PubMed ID: 27388275
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Clinical value of serum CA19-9, CA125 and CP2 in mucinous ovarian tumor: a retrospective study of 273 patients].
    Dong L; Cui H; Li XP; Sun LF; Chang XH; Liang XD; Zhu HL
    Zhonghua Fu Chan Ke Za Zhi; 2008 Jan; 43(1):5-8. PubMed ID: 18366923
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The utility of presurgical CA125 to predict optimal tumor cytoreduction of epithelial ovarian cancer.
    Barlow TS; Przybylski M; Schilder JM; Moore DH; Look KY
    Int J Gynecol Cancer; 2006; 16(2):496-500. PubMed ID: 16681717
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preoperative CA-125 levels in 123 patients with borderline ovarian tumors: a retrospective analysis and review of the literature.
    Kolwijck E; Thomas CM; Bulten J; Massuger LF
    Int J Gynecol Cancer; 2009 Nov; 19(8):1335-8. PubMed ID: 20009886
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Borderline ovarian tumors: French guidelines from the CNGOF. Part 2. Surgical management, follow-up, hormone replacement therapy, fertility management and preservation.
    Bourdel N; Huchon C; Abdel Wahab C; Azaïs H; Bendifallah S; Bolze PA; Brun JL; Canlorbe G; Chauvet P; Chereau E; Courbiere B; De La Motte Rouge T; Devouassoux-Shisheboran M; Eymerit-Morin C; Fauvet R; Gauroy E; Gauthier T; Grynberg M; Koskas M; Larouzee E; Lecointre L; Levêque J; Margueritte F; D'argent Mathieu E; Nyangoh-Timoh K; Ouldamer L; Raad J; Raimond E; Ramanah R; Rolland L; Rousset P; Rousset-Jablonski C; Thomassin-Naggara I; Uzan C; Zilliox M; Daraï E
    J Gynecol Obstet Hum Reprod; 2021 Jan; 50(1):101966. PubMed ID: 33144266
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent.
    Silva EG; Gershenson DM; Malpica A; Deavers M
    Am J Surg Pathol; 2006 Nov; 30(11):1367-71. PubMed ID: 17063075
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognosis in patients with serous and mucinous stage I borderline ovarian tumors.
    Song T; Lee YY; Choi CH; Kim TJ; Lee JW; Kim BG; Bae DS
    Int J Gynecol Cancer; 2012 Jun; 22(5):770-7. PubMed ID: 22426410
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Clinicopathologic analysis of 130 cases of mucinous borderline ovarian tumors].
    Cao DY; Shen K; Tao T; Yang JX; Xiang Y; Huang HF; Wu M; Pan LY; Lang JH
    Zhonghua Fu Chan Ke Za Zhi; 2011 Jan; 46(1):15-8. PubMed ID: 21429428
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of stage III mucinous and serous ovarian cancer: a case-control study.
    Firat Cuylan Z; Karabuk E; Oz M; Turan AT; Meydanli MM; Taskin S; Sari ME; Sahin H; Ulukent SC; Akbayir O; Gungorduk K; Gungor T; Kose MF; Ayhan A
    J Ovarian Res; 2018 Oct; 11(1):91. PubMed ID: 30376858
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Accuracy of intraoperative frozen section for the evaluation of ovarian neoplasms: an institutional experience.
    Hashmi AA; Naz S; Edhi MM; Faridi N; Hussain SD; Mumtaz S; Khan M
    World J Surg Oncol; 2016 Mar; 14():91. PubMed ID: 27029917
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A retrospective analysis of borderline ovarian tumors in a Greek university hospital.
    Liapis A; Bakalianou K; Iavazzo C; Salakos N; Paltoglou G; Kondi-Pafiti A
    Eur J Gynaecol Oncol; 2008; 29(4):383-5. PubMed ID: 18714575
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Borderline ovarian tumors. Retrospective analysis of 20 cases].
    Iervolino P; Palmieri M; Rotondi M; D'Alessandro P; Iuliano R
    Minerva Ginecol; 2001 Feb; 53(1 Suppl 1):97-9. PubMed ID: 11526732
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oviductal glycoprotein (OVGP1, MUC9): a differentiation-based mucin present in serum of women with ovarian cancer.
    Maines-Bandiera S; Woo MM; Borugian M; Molday LL; Hii T; Gilks B; Leung PC; Molday RS; Auersperg N
    Int J Gynecol Cancer; 2010 Jan; 20(1):16-22. PubMed ID: 20130498
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical value of CA125, CA19-9, CEA, CA72-4, and TPA in borderline ovarian tumor.
    Tamakoshi K; Kikkawa F; Shibata K; Tomoda K; Obata NH; Wakahara F; Tokuhashi Y; Ishikawa H; Kawai M; Tomoda Y
    Gynecol Oncol; 1996 Jul; 62(1):67-72. PubMed ID: 8690294
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.